Exogenous administration of IL1β has been shown to exacerbate ischemic damage, whereas administration of an endogenous IL-1β receptor antagonist [23] or a neutralizing antibody [24] reduced brain damage and edema when administered before a stroke in rats. Here, IL1B is linked to stroke disorder.